Cann Group Ltd
ASX:CAN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Cann Group Ltd
Capital Expenditures
Cann Group Ltd
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cann Group Ltd
ASX:CAN
|
Capital Expenditures
-AU$193k
|
CAGR 3-Years
70%
|
CAGR 5-Years
44%
|
CAGR 10-Years
N/A
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Capital Expenditures
-AU$9k
|
CAGR 3-Years
37%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Capital Expenditures
-AU$29m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Capital Expenditures
-AU$37k
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-44%
|
CAGR 10-Years
-29%
|
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Capital Expenditures
-AU$182.7k
|
CAGR 3-Years
5%
|
CAGR 5-Years
-66%
|
CAGR 10-Years
N/A
|
|
|
Nyrada Inc
ASX:NYR
|
Capital Expenditures
-AU$2.2k
|
CAGR 3-Years
1%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Cann Group Ltd
Glance View
Cann Group Ltd. operates research and development and cultivation facilities to grow medicinal cannabis. The company is headquartered in Melbourne, Victoria. The company went IPO on 2017-05-04. The firm has established research and cultivation facilities in Melbourne and is developing a cultivation facility near Mildura, Victoria. The company focuses on developing and supplying cannabis, cannabis resin and medicinal cannabis products into the Australian market. The firm has a cannabis research license and cannabis cultivation license. The cannabis cultivation license allows the Company to produce Australian grown material that can be prescribed for patient use. The company focuses on plant genetics, breeding, cultivation, extraction, analysis and production techniques to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions.
See Also
What is Cann Group Ltd's Capital Expenditures?
Capital Expenditures
-193k
AUD
Based on the financial report for Dec 31, 2025, Cann Group Ltd's Capital Expenditures amounts to -193k AUD.
What is Cann Group Ltd's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
44%
Over the last year, the Capital Expenditures growth was 22%. The average annual Capital Expenditures growth rates for Cann Group Ltd have been 70% over the past three years , 44% over the past five years .
